Receives Fast Track News Today : Breaking News, Live Updates & Top Stories | Vimarsana

VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis Vedanta’s pipeline also includes VE303, its Phase 3 ready therapeutic.

United kingdomUnited statesJeffrey silberDrug administrationPuretech healthFounded entityVedanta biosciencesFast trackBiosciences announces first patient dosedUlcerative colitisReceives fast trackChief medical officerFounded entitiesPrivate securities litigation reform actTrack designationAnnual report